These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23071528)

  • 1. Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial.
    Braun M; Young J; Reiner CS; Poster D; Krauer F; Kistler AD; Kristanto P; Wang X; Liu Y; Loffing J; Andreisek G; von Eckardstein A; Senn O; Wüthrich RP; Serra AL
    PLoS One; 2012; 7(10):e45868. PubMed ID: 23071528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian toxicity from sirolimus.
    Braun M; Young J; Reiner CS; Poster D; Wüthrich RP; Serra AL
    N Engl J Med; 2012 Mar; 366(11):1062-4. PubMed ID: 22417271
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.
    Riegersperger M; Herkner H; Sunder-Plassmann G
    Trials; 2015 Apr; 16():182. PubMed ID: 25899445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.
    Ruggenenti P; Gentile G; Perico N; Perna A; Barcella L; Trillini M; Cortinovis M; Ferrer Siles CP; Reyes Loaeza JA; Aparicio MC; Fasolini G; Gaspari F; Martinetti D; Carrara F; Rubis N; Prandini S; Caroli A; Sharma K; Antiga L; Remuzzi A; Remuzzi G;
    Clin J Am Soc Nephrol; 2016 May; 11(5):785-794. PubMed ID: 26912555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.
    Serra AL; Kistler AD; Poster D; Struker M; Wüthrich RP; Weishaupt D; Tschirch F
    BMC Nephrol; 2007 Sep; 8():13. PubMed ID: 17868472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
    Bachmann F; Glander P; Budde K; Bachmann C
    J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.
    Serra AL; Kistler AD; Poster D; Krauer F; Senn O; Raina S; Pavik I; Rentsch K; Regeniter A; Weishaupt D; Wüthrich RP
    Nephrol Dial Transplant; 2009 Nov; 24(11):3334-42. PubMed ID: 19525519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    Liu YM; Shao YQ; He Q
    Transplant Proc; 2014; 46(1):66-74. PubMed ID: 24507028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
    Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study.
    Davis S; Gralla J; Chan L; Wiseman A; Edelstein CL
    Transplant Proc; 2018 Jun; 50(5):1243-1248. PubMed ID: 29880342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option].
    Serra AL; Wüthrich RP
    Praxis (Bern 1994); 2009 Dec; 98(25):1511-6. PubMed ID: 20013687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus therapy to halt the progression of ADPKD.
    Perico N; Antiga L; Caroli A; Ruggenenti P; Fasolini G; Cafaro M; Ondei P; Rubis N; Diadei O; Gherardi G; Prandini S; Panozo A; Bravo RF; Carminati S; De Leon FR; Gaspari F; Cortinovis M; Motterlini N; Ene-Iordache B; Remuzzi A; Remuzzi G
    J Am Soc Nephrol; 2010 Jun; 21(6):1031-40. PubMed ID: 20466742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP; Kistler AD; Serra AL
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis.
    Xue C; Dai B; Mei C
    Nephron Clin Pract; 2013; 124(1-2):10-6. PubMed ID: 24022660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
    Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
    Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of ovarian cysts in premenopausal women receiving sirolimus and tacrolimus after clinical islet transplantation.
    Alfadhli E; Koh A; Albaker W; Bhargava R; Ackerman T; McDonald C; Ryan EA; Shapiro AM; Senior PA
    Transpl Int; 2009 Jun; 22(6):622-5. PubMed ID: 19207188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
    Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
    J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M; Arcaro A; Varga Z; Vogetseder A; Le Hir M; Wüthrich RP; Serra AL
    Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease.
    Wüthrich RP; Serra AL
    Transplant Proc; 2009; 41(6 Suppl):S18-20. PubMed ID: 19651290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.